Title: Tu2024 A Randomized Double-Blind Placebo-Controlled Trial of a Multi-Strain Probiotic in Treatment of Chronic Symptoms in Diverticular Disease
Abstract: TH 17 cell differentiation in vitro.When naïve CD4 + T cells were stimulated in a medium containing components for T H 17 cell differentiation, the % of IL17A-producing CD4 + T cells and RORg-expressing CD4 + T cells (T H 17) were significantly increased compared to T H 0 cells.LR17938 treatment inhibited the % of IL17A-producing (from 10.5±2.6% to 0.5±0.1%,p<0.001) and the percentage of RORg-expressing cells (from 8.9±1.4% to 2.5±0.7%,p<0.01)T H 17 cells.When we assessed the effect of LR17938 on transcriptional activity by using HEK293T cells transiently transfected with GAL4-DBD/ROR a/g -LBD and GAL4 promoter plasmids followed by treatment with LR17938 culture (LRc), LR17938 bacteria (LRb) and LR17938 culture supernatant (LRs), respectively, we found that LRc, LRb and LRs all inhibited RORa or RORg-dependent reporter activity in a dose-dependent manner.LR17938 treatment also inhibited IL-17 promoter activity in EL4 cells co-transfected with ROR a or RORg and the IL17A promoter reporter.CONCLUSIONS: Probiotic LR17938 and its secreted products suppress T H 17 cell differentiation via antagonizing RORa/g activity.LR17938 may be beneficial in treating T H 17-mediated inflammatory diseases.
Publication Year: 2016
Publication Date: 2016-04-01
Language: en
Type: article
Indexed In: ['crossref']
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot